Enhanced antitumor effect of combined-modality treatment using convection-enhanced delivery of hydrophilic nitrosourea with irradiation or systemic administration of temozolomide in intracranial brain tumor xenografts

Neurological Research

Volumn 30, Issue 9, 2008, Pages 960-967

  Sugiyama, Shin Ichiro ^a   Yamashita, Yoji ^a   Kikuchi, Toshio ^a   Sonoda, Yukihiko ^a   Kumabe, Toshihiro ^a   Tominaga, Teiji ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Brain tumor; Convection enhanced delivery; Nimustine hydrochloride; Radiotherapy; Temozolomide

Indexed keywords

NIMUSTINE; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN RADIATION; BRAIN TUMOR; CANCER MODEL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CONVECTION ENHANCED DELIVERY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG INFUSION; DRUG SAFETY; HYDROPHILICITY; LONG TERM CARE; MALE; MULTIMODALITY CANCER THERAPY; NONHUMAN; RADIATION DOSE; RAT; SPRAGUE DAWLEY RAT; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CONVECTION; CRANIAL IRRADIATION; DACARBAZINE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GLIOSARCOMA; INJECTIONS, INTRAPERITONEAL; MALE; NIMUSTINE; RATS; RATS, INBRED F344; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57349167274     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313208X331581     Document Type: Article

References (35)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996
2. Groothuis DR. The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery. Neurooncology 2000; 2: 45-59
3. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-1018
4. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002; 41: 403-419
5. Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994; 91: 2076-2080
6. Lieberman DM, Laske DW, Morrison PF, et al. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 1995; 82: 1021-1029
7. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: Presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 2003; 88: 105-111
8. Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. J Neurosurg 2004; 100: 472-479
9. Mardor Y, Roth Y, Lidar Z, et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 2001; 61: 4971-4973
10. Popperl G, Goldbrunner R, Gildehaus FJ, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2005; 32: 1018-1025
11. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003; 65: 3-13
12. Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007; 25: 837-844
13. Weber F, Asher A, Bucholz R, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 2003; 64: 125-137
14. Sampson JH, Akabani G, Archer GE, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003; 65: 27-35
15. Barth RF, Yang W, Al-Madhoun AS, et al. Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors. Cancer Res 2004; 64: 6287-6295
16. Yang W, Barth RF, Adams DM, et al. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas. Cancer Res 2002; 62: 6552-6558
17. Noble CO, Krauze MT, Drummond DC, et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: Pharmacology and efficacy. Cancer Res 2006; 66: 2801-2806
18. Saito R, Krauze MT, Noble CO, et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neurooncology 2006; 8: 205-214
19. Yamashita Y, Krauze MT, Kawaguchi T, et al. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neurooncology 2007; 9: 20-28
20. Patel SJ, Shapiro WR, Laske DW, et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: Initial experience in 51 patients. Neurosurgery 2005; 56: 1243-1252
21. Bruce JN, Falavigna A, Johnson JP, et al. Intracerebral clysis in a rat glioma model. Neurosurgery 2000; 46: 683-691
22. Heimberger AB, Archer GE, McLendon RE, et al. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin Cancer Res 2000; 6: 4148-4153
23. Sugiyama S, Yamashita Y, Kikuchi T, et al. Safety and efficacy of convection-enhanced delivery of ACNU, a hydrophilic nitrosourea, in intracranial brain tumor models. J Neurooncol 2007; 82: 41-47
24. Saito R, Bringas JR, McKnight TR, et al. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res 2004; 64: 2572-2579
25. Krauze MT, Saito R, Noble C, et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 2005; 103: 923-929
26. Mori T, Mineura K, Katakura R. Chemotherapy of malignant brain tumor by a water-soluble anti-tumor nitrosourea, ACNU. Neurol Med Chir (Tokyo) 1979, 19: 1157-1171
27. Saito R, Bringas JR, Panner A, et al. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 2004; 64: 6858-6862
28. Shapiro WR, Young DF. Neurological complications of antineoplastic therapy. Acta Neurol Scand Suppl 1984; 100: 125-132
29. Vavra M, Ali MJ, Kang EW, et al. Comparative pharmacokinetics of 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery. Neurooncology 2004; 6: 104-112
30. Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J Neurooncol 2005; 73: 57-69
31. Steinbok P, Mahaley MS, U R, et al. Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model. J Neurosurg 1979; 51: 581-586
32. Tofilon PJ, Williams ME, Deen DF. The effects of X rays on BCNU-induced DNA crosslinking. Radiat Res 1984; 99: 165-174
33. Clark AS, Deans B, Stevens MF, et al. Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. J Med Chem 1995; 38: 1493-1504
34. Brandes AA, Turazzi S, Basso U, et al. A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology 2002; 58: 1759-1764
35. Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 2000; 6: 3878-3884